| GTO ID | GTC3487 |
| Trial ID | NCT05916261 |
| Disease | Pancreatic Cancer |
| Therapy | mRNA vaccine |
| Treatment | mRNA-0217/S001 |
| Co-treatment | Pembrolizumab |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | Clinical Study of Personalized Tumor Vaccines mRNA-0217/S001 and Pabolizumab in Patients With Advanced Pancreatic Cancer |
| Year | 2023 |
| Country | China |
| Company sponsor | Ruijin Hospital |
| Other ID(s) | 2022PCV001 |
| Cohort 1 | |||||||
|
|||||||